XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
January 03 2006 - 1:48AM
PR Newswire (US)
REHOVOT, Israel, January 3 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals, Ltd. ("XTLbio")
(LSE:XTL)(NASDAQ:XTLB)(TASE:XTL), a biopharmaceutical company
developing drugs against hepatitis, announced today the appointment
of Ron Bentsur as Chief Executive Officer of the Company. Ron
Bentsur is based in the US. Michael S. Weiss, Chairman of XTLbio's
Board of Directors, stated, "On behalf of the Board, I want to
welcome Ron Bentsur to XTLbio. Ron is an experienced biotechnology
executive with a track record for assisting in creating shareholder
value. I believe that Ron's excellent and longstanding
relationships with the biotechnology investment, research and
banking communities in the US and Europe will be a true asset to
the Company. I am confident that under Ron's dedicated leadership,
XTLbio will continue along its trajectory towards success and
become a major player in the biotechnology sector." "I am extremely
excited about this opportunity," said Mr. Bentsur. "I look forward
to working with the XTLbio management team to continue to build
long-term value in the Company. I am eager to begin to leverage our
capabilities to position the Company for long-term success." Ron
Bentsur has nearly a decade of experience in the biotech industry.
Most recently, Mr. Bentsur served as Vice President, Finance and
Investor Relations of Keryx Biopharmaceuticals, a position he has
held since June 2003. From October 2000 to June 2003, Mr. Bentsur
served as Director of Investor Relations at Keryx. From July 1998
to October 2000, he served as Director of Technology Investment
Banking at Leumi Underwriters, where he was responsible for all
technology/biotechnology private placement and advisory
transactions. From June 1994 to July 1998, Mr. Bentsur worked as an
investment banker at ING Barings Furman Selz. Mr. Bentsur holds a
BA in Economics and Business Administration with distinction from
the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum
Laude, from New York University's Stern Graduate School of
Business. During an interim transitional period, Mr. Bentsur will
continue to serve as Vice President, Finance and Investor Relations
of Keryx Biopharmaceuticals, Inc. Contact XTLbio: Jonathan Burgin,
Chief Financial Officer, Tel: +972-8-930-4440 About XTLbio XTL
Biopharmaceuticals Ltd ("XTLbio") is engaged in the research,
development and commercialization of therapeutics for the treatment
of infectious diseases, with a particular focus on hepatitis C.
XTLbio's most advanced therapeutic in Hepatitis C is XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C
virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTLbio's second Hepatitis C therapeutic is
XTL-2125 - a small molecule inhibitor of the hepatitis C Virus
polymerase - expected to enter Phase 1 clinical trials in 1H2006.
XTLbio hepatitis C pipeline also includes several families of
pre-clinical hepatitis C small molecule inhibitors. In 2004, XTLbio
licensed HepeX-B - an antibody therapeutic against hepatitis B - to
Cubist Pharmaceuticals. XTLbio is publicly traded on the London,
NASDAQ, and Tel-Aviv Stock Exchanges
(LSE:XTL)(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL
Biopharmaceuticals Ltd. CONTACT: XTLbio: Jonathan Burgin, Chief
Financial Officer, Tel: +972-8-930-4440
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024